bupivacaine has been researched along with transforming growth factor beta in 3 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (33.33) | 29.6817 |
2010's | 1 (33.33) | 24.3611 |
2020's | 1 (33.33) | 2.80 |
Authors | Studies |
---|---|
Kitajima, S; Sakamoto, K; Sakuma, K; Sano, M; Totsuka, T; Uramoto, I; Watanabe, K | 1 |
Davis, MS; Kamath, H; Maguire, T; Manchikalapati, D; Marrero-Berrios, I; Perez, I; Radhakrishnan, P; SchianodiCola, J; Schloss, RS; Yarmush, J | 1 |
Akashi, M; Amano-Iga, R; Arimoto, S; Hasegawa, T; Hirota, J; Inui, A; Saito, I; Takeda, D; Yatagai, N | 1 |
3 other study(ies) available for bupivacaine and transforming growth factor beta
Article | Year |
---|---|
The adaptive response of transforming growth factor-beta 2 and -beta RII in the overloaded, regenerating and denervated muscles of rats.
Topics: Animals; Bupivacaine; Female; Immunohistochemistry; Male; Muscle Denervation; Muscle Fibers, Fast-Twitch; Muscle Fibers, Slow-Twitch; Muscle, Skeletal; Protein Serine-Threonine Kinases; Rats; Rats, Wistar; Receptor, Transforming Growth Factor-beta Type II; Receptors, Transforming Growth Factor beta; Reference Values; Regeneration; Sciatic Nerve; Time Factors; Transforming Growth Factor beta; Weight-Bearing | 2000 |
Alginate-liposomal construct for bupivacaine delivery and MSC function regulation.
Topics: Alginates; Anesthetics, Local; Bupivacaine; Cells, Cultured; Dinoprostone; Glucuronic Acid; Hexuronic Acids; Humans; Interleukin-6; Liposomes; Mesenchymal Stem Cells; Transforming Growth Factor beta; Tumor Necrosis Factor-alpha | 2018 |
Local application of a transcutaneous carbon dioxide paste prevents excessive scarring and promotes muscle regeneration in a bupivacaine-induced rat model of muscle injury.
Topics: Animals; Bupivacaine; Carbon Dioxide; Cicatrix; Interleukin-6; Muscle, Skeletal; Muscles; Myogenin; Quality of Life; Rats; Rats, Sprague-Dawley; Regeneration; Transforming Growth Factor beta | 2023 |